Login to Your Account



NewCo News

Ziarco Launches with $27M Series A, Assets from Pfizer

By Nuala Moran
Staff Writer

Wednesday, November 7, 2012
LONDON – Four Pfizer Inc. scientists and executives have formed a new company specializing in inflammatory and allergic diseases around assets deemed surplus to requirements following the closure of the U.S. pharma company's UK R&D center in Sandwich, Kent.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription